|
The number of clinical trials and programs conducted in Europe is increasing, due in part to the move toward standardization (the European Clinical Trials Directive) and the opportunities for patient recruitment in Central and Eastern Europe.
In addition, growing awareness that pharmaceutical research is an important benefit for each country has increased confidence and reduced bureaucracy, further making Europe an attractive location to biopharmaceutical companies for their clinical trials.
New legislation on the horizon, specifically a new pediatric regulation to be implemented by the European Commission during late 2006 or early 2007, will increase the number of large pediatric studies required, presenting increased global opportunity.
Top reasons to conduct a clinical trial in Europe
- The EU Clinical Trials Directive – helps standardize regulatory submissions and data within the European Union.
- World-class Clinical Pharmacology Unit – Kendle’s 50-bed facility in The Netherlands carries out high-quality Phase I and IIa clinical studies.
- Oncology expertise – oncology is a therapeutic focus for a number of Western European countries, especially France and the United Kingdom.
- Access to important patient populations in Central and Eastern Europe (CEE) – biopharmaceutical companies are looking increasingly to ascending markets to balance their patient recruitment.
- Proven reliability of feasibility data – good prediction of recruitment planning, less need for contingency plans.
|
